Bliss GVS Pharma Q1 FY27 Results: Revenue Rs 285 Cr, PAT Rs 51 Cr and Key Highlights
- August 13, 2026
- Posted by: Lakshit Sharma
- Category: Market
Bliss GVS Pharma Q1 FY27: Revenue Rs 285 Cr (+37.65% YoY). PAT Rs 51 Cr (+15.80% YoY). Results August 12, 2026. CMP Rs 514.
Quick Answer
Bliss GVS Pharma reported a 16% jump in net profit to Rs 51 crore in Q1 FY27, compared with Rs 44 crore in the same quarter last year. Revenue climbed 38% to Rs 285 crore during the June 2026 quarter, with gross profit expanding significantly to Rs 66 crore. Investors should track the recovery trajectory and operating cost trends through the rest of FY27.
Bliss GVS Pharma Q1 FY27 results were declared on August 12, 2026, with the pharmaceuticals and healthcare company reporting a net profit (PAT) of Rs 51 crore, up 15.80% from Rs 44 crore in Q1 FY26. The figures are on a consolidated basis for the quarter ended June 30, 2026.
The June 2026 quarter saw sharp growth in Bliss GVS Pharma’s revenue, which climbed 38% year on year to Rs 285 crore. Gross profit for the period stood at Rs 66 crore, up from Rs 33 crore a year earlier.
Click Here – Get Free Investment Predictions
Bliss GVS Pharma Q1 FY27 Financial Highlights
The table below breaks down the key financial figures from the Bliss GVS Pharma Q1 FY27 results against Q1 FY26.
| Metric | Q1 FY27 (Jun 2026) | Q1 FY26 (Jun 2025) | YoY Change |
|---|---|---|---|
| Revenue from Operations (Rs Cr) | Rs 285 Cr | Rs 207 Cr | +37.65% |
| Gross Profit (Rs Cr) | Rs 66 Cr | Rs 33 Cr | +100.62% |
| Net Profit / (Loss) – PAT (Rs Cr) | Rs 51 Cr | Rs 44 Cr | +15.80% |
Bliss GVS Pharma Q1 FY27 Results Performance Analysis
Use the Univest Screener to Track Live Fundamentals of Indian Stocks
The Bliss GVS Pharma Q1 FY27 results show revenue growth of 37.65% year on year to Rs 285 crore. Gross profit improved to Rs 66 crore from Rs 33 crore in Q1 FY26.
Net profit in the June 2026 quarter stood at Rs 51 crore, up 15.80% from Rs 44 crore in Q1 FY26. Investors should verify all figures against the company’s official filings on BSE and NSE.
Key Business Factors in Bliss GVS Pharma Q1 FY27
1. Revenue Growth Expanded the Top Line
37.65% revenue growth year on year reflects strengthening demand in the Pharmaceuticals and Healthcare segment. The June 2026 quarter benefited from higher volumes and improved pricing.
2. Gross Profit Trend
Gross profit rose to Rs 66 crore from Rs 33 crore in Q1 FY26. Better raw material costs and pricing power supported the improvement.
3. Net Profit Rose Quarter on Quarter
Net profit came in at Rs 51 crore, up 15.80% from Rs 44 crore in Q1 FY26. The double-digit profit growth signals solid earnings quality in the current business cycle.
Dividend Details
No dividend has been announced along with the Bliss GVS Pharma Q1 FY27 results for the quarter ended June 2026. Investors can check future dividend updates on BSE and NSE.
Bliss GVS Pharma FY27 Outlook After Q1 Results
The June 2026 quarter results lay a reasonable foundation for FY27. Revenue growth of 37.65% combined with a net profit (PAT) of Rs 51 crore shows the company is firing on most cylinders. Investors tracking the Bliss GVS Pharma Q1 FY27 results should watch for management commentary on demand trends in Pharmaceuticals and Healthcare, raw material cost outlook, and any capex or expansion plans that could shape FY27 earnings.
Bliss GVS Pharma Stock Performance
Download the Univest iOS App or Univest Android App to track Bliss GVS Pharma share price and upcoming results.
Bliss GVS Pharma shares were trading at Rs 514 on August 12, 2026, the day the Pharmaceuticals and Healthcare company announced its Q1 FY27 results. Post-results price action will depend on how the market interprets the revenue and profit trajectory. Always check the latest price on NSE and BSE before making any investment decision.
Key Risks After Bliss GVS Pharma Q1 FY27 Results
1. Demand Slowdown in Pharmaceuticals and Healthcare
A pullback in Pharmaceuticals and Healthcare demand could weigh on revenue growth and make it harder to sustain the profitability levels seen in Q1 FY27.
2. Input Cost and Margin Pressure
Rising raw material costs or an unfavourable sales mix could squeeze gross margins and limit net profit improvement through the rest of FY27.
3. Macro and Regulatory Headwinds
Broader factors such as interest rate movements, currency volatility, and sector-specific regulatory changes remain risks to watch for the remainder of FY27.
Conclusion
The Bliss GVS Pharma Q1 FY27 results show revenue of Rs 285 crore and a net profit (PAT) of Rs 51 crore, up 15.80% from Rs 44 crore in Q1 FY26. The performance reflects the company’s current standing in the Pharmaceuticals and Healthcare space. Investors should go through the detailed financial statements on BSE and NSE and seek advice from a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Bliss GVS Pharma Q1 FY27 Results
When were the Bliss GVS Pharma Q1 FY27 results announced?
Ans. The Bliss GVS Pharma Q1 FY27 results were announced on August 12, 2026. The consolidated financials cover the quarter ended June 30, 2026, and were filed with the BSE and NSE on the same date.
What was the net profit in the Bliss GVS Pharma Q1 FY27 results?
Ans. Net profit (PAT) stood at Rs 51 crore in Q1 FY27, up 15.80% from Rs 44 crore in Q1 FY26.
What was the revenue in the Bliss GVS Pharma Q1 FY27 results?
Ans. Revenue for the June 2026 quarter grew 37.65% year on year to Rs 285 crore from Rs 207 crore in Q1 FY26.
Did Bliss GVS Pharma declare a dividend with Q1 FY27 results?
Ans. No dividend has been declared alongside the Bliss GVS Pharma Q1 FY27 results for the June 2026 quarter. Any future dividend announcements will be available on the BSE and NSE portals.
What is the FY27 outlook for Bliss GVS Pharma after Q1 results?
Ans. The June 2026 quarterly performance signals a positive trajectory for FY27. Key factors to watch include demand trends in the Pharmaceuticals and Healthcare sector, margin performance, and management guidance for the year.
Is Bliss GVS Pharma a good stock to buy after Q1 FY27 results?
Ans. The Q1 FY27 results of Bliss GVS Pharma provide insight into the company’s financial health, but investment decisions should never be based on one quarter alone. This article is for educational purposes and does not constitute investment advice. Please consult a SEBI-registered advisor before making any investment decision.